![Missouri Department of Health & Senior Services on Twitter: "You may have heard that you don't have to quarantine after you receive a COVID-19 vaccine. Here is a breakdown of timing for Missouri Department of Health & Senior Services on Twitter: "You may have heard that you don't have to quarantine after you receive a COVID-19 vaccine. Here is a breakdown of timing for](https://pbs.twimg.com/media/ExVi6WKWUAMv6AF.jpg)
Missouri Department of Health & Senior Services on Twitter: "You may have heard that you don't have to quarantine after you receive a COVID-19 vaccine. Here is a breakdown of timing for
![Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day](https://mms.businesswire.com/media/20210413006131/en/871212/4/Finance_slide_Final.jpg)
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day
![Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine | Nature Communications Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-30059-3/MediaObjects/41467_2022_30059_Fig1_HTML.png)
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine | Nature Communications
![Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7013e3_COVIDVaccineFieldEffectiveness_IMAGE_29Mar21_v2_1200x627.jpg?_=23735)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December
![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x627.jpg?_=39294)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ](https://www.bmj.com/content/bmj/373/bmj.n1087/F5.medium.jpg)
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://www.thelancet.com/cms/attachment/c0547203-d7c7-4471-bd9b-1440f4613981/gr1_lrg.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01446-y/MediaObjects/41591_2021_1446_Fig1_HTML.png)
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine
![Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ](https://www.bmj.com/content/bmj/373/bmj.n1087/F3.medium.jpg)
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
![Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA](https://www.fda.gov/files/Booster%20Infographic_D_Rev_010622_0.png)